FDA Committee Votes to Recommend Schedule II Status for Hydrocodone Combination Drugs
February 4, 2013 at 09:41:00 ET
The Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee voted 19 to 10 in favor of removing hydrocodone combination drugs from their current Schedule III status and placing them on Schedule II. Rescheduling the products to Schedule II would subject them to more stringent requirements regarding storage, recordkeeping and prescribing, such as limitation... Read More
